Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
NanoCor Therapeutics, Inc.
Download detailed PDF Members: NanoCor Therapeutics, Inc. ("NanoCor") is a biotechnology company founded to create the first viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure ("CHF"). The company was spun off from Asklepios BioPharmaceutical, Inc. in August 2005.CHF is the end product of a number of cardiovascular diseases that degrade the heart's ability to pump blood efficiently. The American Heart Association estimates that approximately five million patients in the United States and over fifteen million patients worldwide are suffering from the disease's often debilitating symptoms - with over 500,000 new cases diagnosed each year.
This page has been viewed 351 times since April 2007, the link to the organisation's website has been followed 62 times Recent Search Terms used to find this page: nanocor | nanocor therapeutics website | . Search for more companies in Chapel Hill Search for more companies in North Carolina This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for NanoCor Therapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||
|